Schrodinger Inc

NASDAQ:SDGR   3:59:57 PM EDT
60.47
+0.23 (+0.38%)
4:48:04 PM EDT: $60.30 -0.17 (-0.28%)
Other Pre-Announcement

Schrodinger Reports Qtrly Loss Per Share $0.49

Published: 08/12/2021 12:51 GMT
Schrodinger Inc (SDGR) - Sees FY Drug Discovery Revenue $22 Million to $32 Million.
SchrÖdinger Reports Second Quarter 2021 Financial Results and Provides Company Update.
Q2 Revenue $29.8 Million Versus Refinitiv Ibes Estimate of $29.9 Million.
Internal Pipeline Progressing With Plans to Submit Up to Three Investigational New Drug Applications to FDA in 2022.
Cash, Cash Equivalents, Restricted Cash and Marketable Securities As of June 30, 2021 Were $616.6 Million.
Qtrly Loss per Share $0.49.
Continues to Expect FY Total Revenue to Range From $124 Million to $142 Million.
Further Company Coverage: .
((reuters.
Briefs@thomsonreuters.
Com;)).